Surface-modified flow diverter p48-MW-HPC: Preliminary clinical experience in 28 patients treated in two centers - 04/05/21
pages | 5 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | This preliminary evaluation of the p48-MW-HPC flow diverter shows high feasibility of aneurysm treatment with this device. |
• | No morbidity or mortality in this preliminary series of patients. |
• | At 6-month a high rate of complete aneurysm occlusion is obtained (87.0%). |
Abstract |
Background and purpose |
Flow diversion is increasingly used for endovascular treatment of distal intracranial aneurysms and has led to the development of small diameter flow diverters such as p48-MW (phenox, Bochum, Germany). Use of flow diverters is limited, however, as patients require dual antiplatelet treatment to avoid thromboembolic complications. Hydrophilic Polymer Coating was developed to reduce platelet aggregation on the p48-MW (p48-MW-HPC). This study reports preliminary experience with p48-MW-HPC in aneurysm treatment in two centers.
Materials and methods |
Patients with ruptured, unruptured, and recanalized aneurysms treated with p48-MW-HPC were prospectively included and retrospectively analyzed for safety and efficacy. Safety was evaluated by analyzing intra- and postoperative complications as well as thromboembolic events depicted by DWI in the 72 h post-procedure. Efficacy was evaluated at 6 months based on aneurysm occlusion.
Results |
From April 2019 to May 2020, 28 patients aged 25–82 years with 29 aneurysms were treated. Two thromboembolic events (7.1%) were reported with good clinical outcome. Final morbidity and mortality were both 0.0%. Post-operative DWI-MRI was depicting lesions in 70.0% of patients. Short-term (6 months) anatomical results were complete aneurysm occlusion in 87.0% of aneurysms, neck remnant in 8.7%, and aneurysm remnant in 4.3%.
Conclusion |
This preliminary clinical evaluation conducted in a relatively small sample size shows high feasibility (100.0%) of p48-MW-HPC aneurysm treatment, without morbidity or mortality, and high efficacy (complete occlusion in 90.0%). Additional larger comparative studies are needed to confirm these results and optimize perioperative antiplatelet treatment.
Le texte complet de cet article est disponible en PDF.Abbreviations : APT, DAPT, FD, HPC, TE
Keywords : Aneurysm, Endovascular treatment, Flow diversion, p48-MW-HPC device
Plan
Vol 48 - N° 3
P. 195-199 - mai 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?